The Carcinoid Tumor Market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.5 billion by 2034, registering a CAGR of 7.5%. This growth trajectory is underpinned by a combination of factors, including the rising incidence of carcinoid tumors, advancements in diagnostic technologies, and an increasing focus on targeted therapies. The demand for effective treatment options is...